Core Viewpoint - The announcement indicates that a subsidiary of the company has received regulatory approval for a new drug, which may enhance its product portfolio and market position in the pharmaceutical industry [2] Group 1 - On December 26, the company announced that its subsidiary, Beijing Jingfeng Pharmaceutical Group Co., Ltd., received a drug registration certificate for Isopropamide Iodide Injection from the National Medical Products Administration [2] - The approval is significant as it allows the company to market and distribute this medication, potentially increasing its revenue streams [2] - The drug registration certificate was issued on December 25, 2025, marking a key milestone in the company's product development timeline [2]

Group 1 - Zhuolang Intelligent's subsidiary plans to increase capital by 900 million yuan to its wholly-owned subsidiary in Xinjiang [1] - Zhenhua Heavy Industry signed a contract worth 1.149 billion yuan with Guangzhou Salvage Bureau for a deep-water crane ship construction project [2] - Ugreen Technology intends to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its global strategy [3] Group 2 - Guangsheng Nonferrous Metals will change its stock name to Zhongxi Rare Metals starting December 31, 2025 [4] - China Electric Research proposed a cash dividend of 2.5 yuan per 10 shares for the first three quarters of 2025 [5] - Chaoyan Co. is establishing a fund with professional investment institutions, aiming to raise 1 billion yuan [6] Group 3 - Silk Road Vision's subsidiary plans to sell 8.5% of Ruijun Technology for 52.7 million yuan [7] - Longgao Co.'s actual controller is transferring 4.37% of the investment development group's equity for 398 million yuan [8] - Weiteou signed a strategic cooperation agreement with Huaruixin Energy to develop new materials and applications [9][10] Group 4 - Annuoqi decided to terminate the investment in a 50,000-ton dye intermediate project due to market changes, with a total investment of 421 million yuan [12] - Akoli's subsidiary has entered trial production for a project with an annual capacity of 20,000 tons of polyether amine [13] - Ningbo Construction's subsidiary signed a construction contract worth 451 million yuan for a comprehensive utility tunnel project [14] Group 5 - Zhejiang Rongtai and Weichuang Electric plan to establish a joint venture in Thailand for R&D and production of mechatronic components [15] - Jiuzhoutong's subsidiary received a drug registration certificate for isopropazine injection [16] - Huaqin Technology's subsidiary signed a daily operation contract worth 392 million yuan [17] Group 6 - ST Meichen completed the sale of 100% equity in Hainan Meichen Ecological Development Co., Ltd. [18] - Pulite's LCP film products have begun mass production for a leading customer in the consumer electronics industry [19][20] - Nanjing Public Utility's major shareholder transferred 7.61% of the company's shares for 300 million yuan [21] Group 7 - Solar Energy terminated the investment in a 150 MW distributed photovoltaic project due to increased investment risks [22] - Yuntian Lifa won a 122 million yuan project for AI development in Longgang [23] - Changchun High-tech's subsidiary received acceptance for a clinical trial application for GenSci141 ointment [24] Group 8 - Changfei Optical Fiber's major shareholder completed a share reduction plan, selling 1.1 million shares for approximately 104.5 million yuan [25] - Sandam Membrane plans to apply for a comprehensive credit limit of up to 100 million yuan for 2026 [26] - Aisecurity received a government subsidy of 3.4611 million yuan [27] Group 9 - Stone Technology's H-share issuance has received approval from the China Securities Regulatory Commission [28] - Hongxing Development's subsidiary plans to suspend production to comply with national hazardous chemical relocation policies [29] - Guodian Nanzi's vice president and chief engineer resigned [30] Group 10 - Jianghe Group's subsidiary won a bid for a city renovation project in Haikou worth approximately 112 million yuan [31] - Gaotie Electric's subsidiary won a bid for a railway project worth 59.0317 million yuan [32] - Huicheng Co. plans to introduce a new partner to its major shareholder [33] Group 11 - Pumen Technology's folic acid testing kit received a medical device registration certificate [34] - Hai Xin Co.'s vitamin B6 injection passed the consistency evaluation for generic drugs [35] - Taiji Group's shareholder plans to merge with its subsidiary [36] Group 12 - Shengyi Electronics adjusted the maximum repurchase price to no more than 144.36 yuan per share [37]

Core Viewpoint - The company announced that its subsidiary, Beijing Jingfeng Pharmaceutical Group Co., Ltd., received approval from the National Medical Products Administration for the registration of Isopropamide Iodide Injection, indicating a significant advancement in its product portfolio [1] Group 1 - The approved drug, Isopropamide Iodide Injection, is an antihistamine used for treating skin and mucosal allergies, motion sickness, and as an adjunct treatment before and after anesthesia, as well as for preventing radiation sickness or drug-induced nausea and vomiting [1] - As of the date of the announcement, the company has invested approximately RMB 4.67 million (unaudited) in the research and development of this drug [1]

Group 1 - The core point of the article is that Jiuzhoutong (600998.SH) announced that its subsidiary, Beijing Jingfeng Pharmaceutical Group Co., Ltd., received approval from the National Medical Products Administration for the drug registration certificate of Isopropamide Iodide Injection [1] - Isopropamide Iodide Injection is an antihistamine drug used for treating skin and mucosal allergies, motion sickness, and as an adjunct treatment before and after anesthesia and surgery, as well as for preventing and treating radiation sickness or drug-induced nausea and vomiting [1]

Core Viewpoint - The approval of the drug "Isopropamide Iodide Injection" by the National Medical Products Administration is a significant milestone for the company, enhancing its product pipeline and market competitiveness [2] Group 1: Company Developments - The subsidiary of the company, Jingfeng Pharmaceutical, received a drug registration certificate for Isopropamide Iodide Injection, an antihistamine used for skin and mucosal allergies and motion sickness [2] - The company has invested approximately 4.67 million yuan in the research and development of this drug [2] Group 2: Market Implications - The approval of this drug is expected to help the company expand its market share and enrich its injectable product line [2] - There are uncertainties regarding production and sales scale due to factors such as national policies and market environment [2]

Core Viewpoint - Kyushu Tong (600998.SH) announced that its subsidiary, Beijing Jingfeng Pharmaceutical Group Co., Ltd., received approval from the National Medical Products Administration for the drug registration certificate of Isopropamide Iodide Injection, indicating a significant development in its product portfolio [1] Group 1 - The approved drug, Isopropamide Iodide Injection, is an antihistamine used for treating skin and mucosal allergies, motion sickness, and as an adjunct treatment before and after anesthesia and surgery [1] - The drug also serves to prevent and treat radiation sickness or drug-induced nausea and vomiting, highlighting its therapeutic versatility [1]